Upstream Bio (UPB) Total Non-Current Liabilities (2023)
Upstream Bio's (UPB) quarterly Total Non-Current Liabilities came in at $6.5 million in Q4 2023.
Upstream Bio (UPB) Total Non-Current Liabilities (2023) Analysis & Trends
Upstream Bio's Total Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $6.5 million for Q4 2023.
- On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $6.5 million in Q4 2023; TTM through Dec 2023 was $6.5 million, a N/A change from a year earlier, with the FY2023 full-year figure at $6.5 million, changed N/A from the prior year.
- Total Non-Current Liabilities was little changed at $6.5 million in Q4 2023 per UPB's latest filing.
- Across five years, Total Non-Current Liabilities topped out at $6.5 million in Q4 2023 and bottomed at $6.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Upstream Bio | 347.73 Mn | 347.73 Mn | -3.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 6.52 Mn |